MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...

Request To Download Free Sample of This Strategic Report @ This country research report on Vietnam Immuno-oncology Market offers comprehensive insights into the market landscape, customer ...

Whether antiretroviral therapy (ART) is always completely suppressive, or HIV might continue to replicate at low levels despite ART in some people with HIV (PWH), is still debated. Here, we ...

TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...

SKYSCRAPER-01 trial for tiragolumab and atezolizumab in NSCLC showed numerical improvements but failed to meet primary endpoints for survival. Experts argue that TIGIT remains a promising target ...

But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

TIGIT inhibitors play a role in modulating immune system control. TIGIT has ligands such as CD155, CD112, and CD113, which are part of the nectin and NECL molecular families. TIGIT downregulates the ...

iTeos Therapeutics focuses on developing immuno-oncology treatments for cancer patients, with a focus on TIGIT-targeted therapies. Read more on ITOS stock here.

Having paid $300 million to enter the TIGIT space by acquiring ociperlimab in 2021, Novartis is now handing the candidate back to BeiGene.

More Than 40 Anti TIGIT Antibodies Are In Clinical Trials Says Kuick ResearchDelhi, June 26, 2023 (GLOBE NEWSWIRE) -- Global Anti TIGIT Antibody Clinical Trials and Companies Insight 2023 Report ...